Mortality of patients with multiple sclerosis: a cohort study in UK primary care
|
|
- Samuel Joseph
- 5 years ago
- Views:
Transcription
1 Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre The Hrvrd community hs mde this rticle openly vilble. Plese shre how this ccess benefits you. Your story mtters Cittion Jick, S. S., L. Li, G. J. Flcone, Z. P. Vssilev, nd M.-A. Wllnder Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre. Journl of Neurology 261 (8): doi: /s s Published Version doi: /s Citble link Terms of Use This rticle ws downloded from Hrvrd University s DASH repository, nd is mde vilble under the terms nd conditions pplicble to Other Posted Mteril, s set forth t nrs.hrvrd.edu/urn-3:hul.instrepos:dsh.current.terms-ofuse#laa
2 J Neurol (2014) 261: DOI /s ORIGINAL COMMUNICATION Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre S. S. Jick L. Li G. J. Flcone Z. P. Vssilev M.-A. Wllnder Received: 23 Mrch 2014 / Accepted: 6 My 2014 / Published online: 18 My 2014 Ó The Author(s) This rticle is published with open ccess t Springerlink.com Abstrct We imed to estimte rtes, cuses nd risk fctors of ll-cuse mortlity in lrge popultion-bsed cohort of multiple sclerosis (MS) ptients compred with ptients without MS. Using dt from the UK Generl Prctice Reserch Dtbse, we identified MS cses dignosed during nd vlidted using ptients originl records where possible. We lso included MS cses during identified nd vlidted in n erlier study. Cses were mtched to up to ten referents without MS by ge, sex, index dte (dte of first MS dignosis for cses nd equivlent reference dte for controls), generl prctice nd length of medicl history before first MS dignosis. Ptients were followed up to identify deths; hzrd rtios (HRs) nd 95 % confidence intervls Electronic supplementry mteril The online version of this rticle (doi: /s ) contins supplementry mteril, which is vilble to uthorized users. S. S. Jick (&) L. Li Boston Collbortive Drug Surveillnce Progrm, Boston University School of Public Helth, 11 Muzzey Street, Lexington, MA 02421, USA e-mil: sjick@bu.edu G. J. Flcone Deprtment of Neurology, Msschusetts Generl Hospitl, Boston, MA, USA G. J. Flcone Deprtment of Epidemiology, Hrvrd School of Public Helth, Boston, MA, USA Z. P. Vssilev Byer HelthCre Phrmceuticls, Whippny, NJ, USA M.-A. Wllnder Deprtment of Public Helth nd Cring Science, Uppsl University, Uppsl, Sweden (CIs) were estimted using Cox-proportionl regression. MS ptients (N = 1,822) hd significntly incresed risk of ll-cuse mortlity compred with referents (N = 18,211); djusted HR 1.7 (95 % CI ). Compred with referents, femle MS ptients hd higher but not significntly different HR for deth thn mles; djusted HR 1.86 (95 % CI ) vs. HR 1.31 (95 % CI ), respectively. The most commonly recorded cuse of deth in MS ptients ws MS (41 %), with higher proportion recorded mong younger ptients. A significntly higher proportion of referents thn MS ptients hd cncer recorded s cuse of deth (40 vs. 19 %). Ptients with MS hve significnt 1.7-fold incresed risk of ll-cuse mortlity compred with the generl popultion. MS is the most commonly recorded cuse of deth mong MS ptients. Keywords Multiple sclerosis Epidemiology Cuse of deth Cohort nlysis Mortlity Introduction Multiple sclerosis (MS) is chronic, progressive neurologicl disorder, nd is the mjor cuse of non-trumtic disbility in young dults [1]. Mortlity rtes re significntly higher in people with MS compred with the generl popultion [2 4], yet cuses of deth nd fctors influencing survivl in MS ptients re not well understood, nd further dt ddressing these questions re needed. One importnt question is to wht extent cn the excess in mortlity rtes observed in MS ptients be ttributed to the disese. Another importnt question is wht re the risk fctors for the disese nd wht influence do they hve on mortlity. Identifying risk fctors, nd understnding their
3 J Neurol (2014) 261: reltive weight on the risk of mortlity, is vitl for improving our bilities to predict survivl nd for implementing blnced therpeutic strtegy. We therefore imed to estimte mortlity rtes, describe cuse-specific mortlity nd identify risk fctors for mortlity in lrge popultion-bsed cohort of MS ptients compred with ptients without MS in the United Kingdom (UK). Methods Dt source We conducted cohort study using prospectively collected dt from the UK Generl Prctice Reserch Dtbse (GPRD). The GPRD comprises the nonymized computerized medicl records of round 6 % of the UK popultion t ny one time [5, 6]. The dtbse is the core of the primry cre dt mnged by the Clinicl Prctice Reserch Dtlink (CPRD), nd contins informtion on ptients demogrphics, clinicl events, nd detils of specilist referrls, hospitl dmissions nd prescriptions. Additionl informtion cn be dded s free text. Prescriptions re issued directly from the GPs computer, hence ll re recorded. Ptients in the GPRD re representtive of the UK popultion with regrd to ge, sex nd geogrphicl distribution. Vlidtion studies hve demonstrted the qulity of the dt in the GPRD to be generlly high [5], nd the dtbse hs been used for severl studies on MS [7 15]. The study protocol ws pproved by the CPRD Independent Scientific Advisory Committee for UK Medicines nd Helthcre products Regultory Agency dtbse reserch. Study design nd MS cse scertinment We identified cohort of incident nd prevlent MS ptients in the GPRD between Jnury 1993 nd December This ws two-step process involving two study periods. Firstly, we identified ll possible nd probble incident MS cses, nd ll prevlent MS cses occurring between Jnury 2001 nd December Secondly, we dded to this cse set, ll incident nd prevlent MS cses identified nd vlidted in our erlier studies conducted on the GPRD (between 1993 nd 2000) [7, 8] from prctices tht were still contributing to the dtbse in To identify incident MS cses between 2001 nd 2006, we identified ptients registered in the GPRD in this study period who hd t lest two continuous yers of registrtion. Ptients with first recorded dignosis for MS were identified s potentil incident cses, nd their computerized medicl records were reviewed. Potentil incident cses were clssified s either probble, possible, or unlikely MS using n overll clinicl impression obtined fter review by neurologist (GJF) of ll vilble dt on dignoses, tretments nd referrls recorded in the ptient record: probble cse, multiple entries of MS dignosis plus tretment nd/or symptom codes; possible cse, t lest one entry of MS dignosis plus codes for tretments or symptoms tht my hve been relted to MS or multiple MS dignoses with no supporting tretment or symptoms codes; unlikely cse, one entry of MS dignosis only nd no supporting tretment or symptoms codes, or the record contined n lternte dignosis such s myotrophic lterl sclerosis. Where vilble, ptients originl clinicl pper records contining clinicl notes, consulttion letters, specilist referrls, test results nd hospitl dischrge letters were retrieved, nd were reviewed by neurologist (GJF) to vlidte the MS dignosis nd clssify the cse. Ech cse ws clssified ccording to the McDonld criteri for MS [16] nd ctegorized s definite, possible or unlikely. For cses where GP comments strongly indicted tht the ptient hd MS but objective dt were unvilble to fulfill the McDonld criteri, fourth ctegory clled probble ws used. Where there ws uncertinty, second neurologist reviewed the ptient records nd finl decision ws reched by consensus. The index dte ws the dte of MS dignosis. Comprison group selection Ech cse ws rndomly mtched to up to 10 referent subjects without recorded dignosis of MS t ny time in the GPRD by yer of birth, sex, index dte, generl prctice nd length of medicl history recorded before the index dte. The index dte for referents ws the dte of dignosis of their mtched MS cse. Follow-up Ptients were followed up from the index dte to identify deths. The end of follow-up ws the dte of ptient s deth, the dte of trnsfer out of the prctice, or the dte of lst dt collection in the dtbse (31 July 2012), whichever cme first. The cuse of deth ws scertined from electronic nd/or originl clinicl pper records. To supplement informtion on cuse of deth recorded in the GP records, we were ble to link to deth registry dt for ptients in prctices in Englnd, nd we requested dt from dditionl electronic GP notes where the cuse of deth ws unknown, but there ws n indiction tht dditionl electronic GP notes were vilble.
4 1510 J Neurol (2014) 261: Covrite informtion Informtion on the following vribles ws extrcted from the dtbse: ge t first MS dignosis, sex, nd lifestyle fctors closest to nd before the first MS dignosis including smoking, body mss index (BMI) nd lcohol buse. Informtion on chronic comorbidities (recorded t ny time in the dtbse), cute illnesses (recorded t or within 1 yer before dignosis or ny time fter), nd comedictions (t or within 6 months before dignosis or ny time fter) were lso extrcted. Comorbidities evluted included both chronic diseses (chronic obstructive pulmonry disese or sthm, depression, dibetes, hypertension, hert disese nd cncer) nd cute illnesses [infections (respirtory, pneumoni/influenz, urinry trct, skin, eye or er, or other), pin (joint, spine, muscle, migrine, eye or er) nd dyspepsi]. Comedictions evluted included ntibiotics, ntidepressnts, skeletl muscle relxnts, ntipsychotics, nti-prkinson s drugs, nticonvulsnts, opioids, non-steroidl nti-inflmmtory drugs (NSAIDs), topicl NSAIDs, other nlgesics, proton pump inhibitors, steroids, topicl steroids, sttins, nd orl contrceptives. We lso clculted the Chrlson Comorbidity Index [17] before the first recorded MS dignosis. We were unble to obtin informtion on use of interferon bet becuse, in the UK, it is mostly prescribed in secondry cre nd is not lwys cptured in GP records. For the 902 MS ptients with originl clinicl records, we retrieved dditionl informtion on MS subtype [relpsing-remitting MS (RRMS), primry progressive MS (PPMS), secondry progressive MS (SPMS) or unknown], nd MS symptoms t onset. These were clssified into four min groups: sensory, motor, optic neuritis nd other. The ltter group included other optic nd visul nomlies, other crnil nerve nomlies, dysrthri nd stheni. Ptients without symptoms recorded were treted s seprte group with missing symptoms. Sttisticl nlyses All definite, probble nd possible MS cses were included in the nlyses. Ptient chrcteristics were described t or before the index dte nd seprtely t the end of follow-up using counts [percentges (%)] for discrete nd ctegoricl vribles, nd mens [stndrd devition (SD)] for continuous vribles. We compred ptients chrcteristics including lifestyle risk fctors, comorbidities nd comedictions between the MS ptients nd referents. For continuous vribles, we used t tests; for ctegoricl vribles, we used Chi squre tests or Fisher s exct tests where necessry. Crude deth rtes with 95 % confidence intervls (CIs) were clculted overll nd strtified by ge t first dignosis, sex nd type of MS. Cuse of deth ws described where possible. Survivl probbilities for fixed ctegoricl vribles relted to ll-cuse mortlity were estimted using Kpln Meier survivl nlyses, both overll nd strtified by ge t first dignosis nd sex. Hzrd rtios (HRs) nd 95 % CIs for ll-cuse mortlity were estimted using Coxproportionl regression models djusted for potentil confounding vribles. Sttisticl nlyses were performed using SAS version 9.2 (SAS Institute, Cry, NC). Results Between Jnury 2001 nd December 2006, 1278 incident nd 63 prevlent MS cses were identified. In ddition, 435 incident nd 46 prevlent MS cses identified between 1993 nd 2000 were retrieved from previous studies [7 10, 12 14], giving totl of 1,822 MS cses (1,507 definite or probble nd 315 possible), mtched to 18,211 referents. Nerly, three qurters of MS cses were femle nd the men ge t dignosis ws 42.1 yers. PPMS ptients were generlly older t dignosis thn RRMS ptients (men ge 50 vs. 40 yers; p \ 0.001), nd more likely to be mle (42.4 vs %; p \ 0.001) nd current smokers (32 vs %, p = 0.30) (Tble 1). The length of follow-up postcohort entry dte ws similr for MS ptients nd their non- MS comprtors: 7.9 yers (rnge 1 dy 19 yers). Chrcteristics of MS vs. referent subjects There were number of significnt differences between the chrcteristics, comorbidities nd comedictions of MS ptients nd their mtched referents (Tbles 1, 2, 3). At the index dte, MS ptients were more likely to be current smokers (p \ 0.05). Within the yer before the index dte, MS ptients overll were more likely to hve hd urinry trct infection (p \ 0.05), PPMS cses were more likely to hve hd n cute respirtory infection (p \ 0.05) nd RRMS cses were more likely to hve hd other infections (p \ 0.05). Both RRMS nd PPMS ptients were more likely to hve history of depression (p \ 0.05), nd to hve received, ntidepressnts, nticonvulsnts, opioids, muscle relxnts nd nti-prkinson s drugs t or within the 6 months before the index dte (p \ 0.05 for ll). In ddition, during this time period, MS ptients overll were more likely to hve received sttins, NSAIDs, systemic glucocorticoids, ntibiotics nd ntipsychotics (p \ 0.05 for ll). Compred with RRMS ptients, PPMS ptients were more likely to receive symptomtic MS tretment (e.g., muscle relxnts; 16.0 vs. 6.5 %; p = ), but were less likely to receive ntibiotics (12.8 vs %; p = ). Compred with referents, t the end of follow-up MS ptients were more likely to be smokers (26.3 vs %)
5 J Neurol (2014) 261: Tble 1 Bsic chrcteristics of MS cses nd mtched referent subjects t cohort entry, overll nd strtified by type of MS Chrcteristic MS cses N = 1,822 N = 18,211 RRMS N = 769 N = 7,690 PPMS N = 125 N = 1,250 Men ge (yers) t cohort entry (index (11.79) 42.0 (11.72) (11.14) (11.15) (10.43) (10.39) dte; SD) Sex Mles 481 (26.40) 4,801 (26.36) 193 (25.10) 1,930 (25.10) 53 (42.40) 530 (42.40) Femles 1,341 (73.60) 13,410 (73.64) 576 (74.90) 5,760 (74.90) 72 (57.60) 720 (57.60) Smoking sttus Current*, 569 (31.23) 4,363 (23.96) 226 (29.39) 1,902 (24.73) 40 (32.00) 289 (23.12) Former 239 (13.12) 2,390 (13.12) 101 (13.13) 963 (12.52) 23 (18.40) 199 (15.92) Never 777 (42.65) 8,921 (48.99) 349 (45.38) 3,807 (49.51) 50 (40.00) 595 (47.60) Unknown 237 (13.01) 2,537 (13.93) 93 (12.09) 1,018 (13.24) 12 (9.60) 167 (13.36) BMI (kg/m 2 ) \ (2.52) 379 (2.08) 17 (2.21) 179 (2.33) 2 (1.60) 18 (1.44) (38.75) 6,948 (38.15) 301 (39.14) 2,980 (38.75) 46 (36.80) 408 (32.64) (23.38) 4,100 (22.51) 187 (24.32) 1,676 (21.79) 39 (31.20) 339 (27.12) C (13.61) 2,406 (13.21) 112 (14.56) 993 (12.91) 12 (9.60) 198 (15.84) Unknown 396 (21.73) 4,378 (24.04) 152 (19.77) 1,862 (24.21) 26 (20.80) 287 (22.96) Alcohol buse 25 (1.37) 370 (2.03) 3 (0.39) 133 (1.73) 5 (4.0) 50 (4.0) Men length of recorded medicl history (yers; SD) Before index dte 7.86 (4.44) 7.97 (4.43) 7.93 (4.50) 8.03 (4.49) 8.83 (4.51) 9.02 (4.52) Follow-up fter index dte 7.85 (4.50) 7.95 (4.49) 8.95 (4.33) 8.18 (4.40) 8.15 (4.32) 8.15 (4.08) For the 894 MS ptients whose type of MS ws determined through originl clinicl records BMI body mss index, MS multiple sclerosis, PPMS primry progressive MS, RRMS relpsing-remitting MS, SD stndrd devition * p \ 0.05 for comprison between ptients with MS nd mtched referent subjects (for ll MS ptients) p \ 0.05 for comprison between ptients with RRMS nd mtched referent subjects Includes 64 ptients with secondry progressive MS to hve BMI \18.5 kg/m 2 (3.6 vs. 2.0 %), history of depression (45.7 vs %), more infections, including pneumoni nd influenz (1.8 vs. 0.9 %), urinry trct infections (10.5 vs. 3.9 %), nd skin infections (11.9 vs. 9.8 %), nd to hve received more comedictions in the prior 6 months (12.3 vs. 8.5 %) (p \ 0.05 for ll) (Online Resource 1). Mortlity rtes Of the 1,822 MS cses, 130 (7.1 %) died during 14,295 person-yers of follow-up, while 573 (3.1 %) referents died during 144,760 person-yers of follow-up. The crude deth rte for MS ptients ws 9.1 (95 % CI ) per 1,000 person-yers compred with 4.0 (95 % CI ) per 1,000 person-yers for the non-ms referents. Mortlity rtes were higher in MS ptients compred with their mtched referents in ech ge group nd for both mles nd femles. Ptients with PPMS hd n lmost twofold greter mortlity rte compred with RRMS ptients (11.8 vs. 5.8 per 1,000 person-yers). However, these deth rtes were similrly higher compred with their corresponding referents; 6.2 vs. 2.9 per 1,000 person-yers for PPMS nd RRMS referents, respectively) (Tble 4). Ptients ged C50 yers t dignosis hd shorter survivl thn those ged \50 yers t dignosis (Fig. 1). For the ltter group, n incresing difference in survivl between MS cses nd their mtched non-ms referents ws observed with incresing length of follow-up. Survivl probbilities were similr for both mle nd femle MS ptients, with 10-yer survivl t 90 nd 93 %, nd 15-yer survivl t 86 nd 87 % for mles nd femles, respectively. Cuse of deth Among MS ptients who died during follow-up, the most commonly recorded cuse of deth ws MS (40.8 %), followed by pneumoni (25.4 %), cncer (18.5 %), crdiovsculr disese (13.9 %) nd non-infectious respirtory diseses (10.0 %). Among decesed referents, cuse of deth ws recorded s pneumoni in 6.8 %, cncer in
6 1512 J Neurol (2014) 261: Tble 2 Comorbidities of MS cses nd mtched referent subjects t cohort entry, overll nd strtified by type of MS Chrcteristic MS cses N = 1,822 N = 18,211 RRMS cses N = 769 N = 7,690 PPMS cses N = 125 N = 1,250 Chronic comorbidities b COPD nd sthm 302 (16.58) 2,890 (15.87) 117 (15.21) 1,245 (16.19) 18 (14.40) 197 (15.76) Depression*,, 508 (27.88) 3,677 (20.19) 188 (24.45) 1,529 (19.88) 45 (36.00) 238 (19.04) Dibetes 35 (1.92) 390 (2.14) 13 (1.69) 141 (1.83) 3 (2.40) 44 (3.52) Hypertension 137 (7.52) 1,544 (8.48) 47 (6.11) 538 (7.00) 13 (10.40) 179 (14.32) Hert disese 34 (1.87) 439 (2.41) 8 (1.04) 119 (1.55) 4 (3.20) 64 (5.12) Cncer 50 (2.74) 558 (3.06) 15 (1.95) 223 (2.90) 5 (4.00) 50 (4.00) Acute comorbidities c Acute respirtory infection 252 (13.83) 2,673 (14.68) 113 (14.69) 1,143 (14.86) 9 (7.20) 171 (13.68) Pneumoni nd influenz 18 (0.99) 169 (0.93) 11 (1.43) 70 (0.91) 1 (0.80) 14 (1.12) Urinry trct infection* 99 (5.43) 683 (3.75) 36 (4.68) 284 (3.69) 8 (6.40) 41 (3.28) Skin infection 164 (9.00) 1,566 (8.60) 68 (8.84) 652 (8.48) 5 (4.00) 96 (7.68) Eye or Er infection 4 (0.22) 33 (0.18) 3 (0.39) 15 (0.20) 0 ( ) 0 ( ) Other infection*, 149 (8.18) 1,256 (6.90) 69 (8.97) 533 (6.93) 5 (4.00) 73 (5.84) Dyspepsi 35 (1.92) 282 (1.55) 11 (1.43) 120 (1.56) 2 (1.60) 23 (1.84) Chrlson Comorbidity Index t cohort entry Low (0) 1,393 (76.45) 14,192 (77.93) 615 (79.97) 6,048 (78.65) 96 (76.80) 931 (74.48) Medium (1 2) 405 (22.23) 3,822 (20.99) 147 (19.12) 1,574 (20.47) 26 (20.80) 296 (23.68) High ([2) 24 (1.32) 197 (1.08) 7 (0.91) 68 (0.88) 3 (2.40) 23 (1.84) For the 894 MS ptients whose type of MS ws determined through originl clinicl records COPD chronic obstructive pulmonry disorder, MS multiple sclerosis, PPMS primry progressive MS, RRMS relpsing-remitting MS * p \ 0.05 for comprison between ptients with MS nd mtched referent subjects (for ll MS ptients) p \ 0.05 for comprison between ptients with RRMS nd mtched referent subjects b c p \ 0.05 for comprison between ptients with PPMS nd mtched referent subjects Includes 64 ptients with secondry progressive MS Ever before, or t cohort entry During the yer before, or t index dte 39.8 % nd crdiovsculr disese in 19.4 %. The higher proportion of cncer deths mong referents compred with the MS ptients (p \ ) is noteworthy. No mteril difference ws found in the proportion of deths recorded s suicide or ccident between MS ptients nd referents; 1.5 nd 1.9 %, respectively. However, these proportions re bsed on only two MS ptients (one suicide) nd 11 referents (two suicides). Additionl dt on cuse of deth re provided in Online Resources 2 nd 3. Among decesed MS ptients, more mles thn femles hd their cuse of deth recorded s crdiovsculr disese (24.4 vs. 9.0 %, p = 0.02) or MS (43.9 vs %, p = 0.62), while more femles thn mles hd cncer recorded s cuse of deth (20.2 vs %, p = 0.45). Ptients older t dignosis (C50 yers) hd higher proportion of deths recorded s due to cncer compred with ptients dignosed t younger ge (\50 yers) (22.4 vs %, p = 0.23), while ptients younger t dignosis hd higher proportion of deths recorded s due to MS (47.6 vs %, p = 0.12) or pneumoni (31.8 vs %, p = 0.11). Risk fctors for mortlity Compred with referents, MS ptients hd significntly incresed risk of ll-cuse mortlity; djusted HR 1.68 (95 % CI ) (Tble 5). Age ws strong effect modifier, with the youngest MS ptients yielding the highest djusted HR 13.2 (95 % CI ) for ptients ged \30 yers t dignosis. Compred with referents, femle MS ptients hd higher overll HR for deth thn mle MS ptients, lthough the HRs were not significntly different; djusted HR 1.86 (95 % CI ) vs. HR 1.31 (95 % CI ). While we observed significntly higher HR for RRMS ptients compred to referents [djusted HR 1.50 (95 % CI )], significntly
7 J Neurol (2014) 261: Tble 3 Comedictions of MS cses nd mtched referent subjects t cohort entry, overll nd strtified by type of MS Chrcteristic All MS cses N = 1,822 N = 18,211 RRMS cses N = 769 N = 7,690 PPMS cses N = 125 N = 1, (3.75) 8 (6.40) 52 (4.16) Comedictions (t cohort entry [index dte] or within the 6 months before) Systemic 180 (9.88) 713 (3.92) 69 (8.97) glucocorticoids*, Antidepressnts*,, 380 (20.86) 1,582 (8.69) 132 (17.17) 662 (8.61) 28 (22.40) 102 (8.16) Anticonvulsnts*,, 122 (6.70) 225 (1.24) 40 (5.20) 88 (1.14) 11 (8.80) 25 (2.00) Antidibetics 24 (1.32) 283 (1.55) 12 (1.56) 112 (1.46) 0 ( ) 30 (2.40) Opioids*,, 345 (18.94) 1,585 (8.70) 122 (15.86) 621 (8.08) 23 (18.40) 133 (10.64) NSAIDs*, 316 (17.34) 1,806 (9.92) 122 (15.86) 710 (9.23) 21 (16.80) 152 (12.16) Sttins* 61 (3.35) 447 (2.45) 20 (2.60) 137 (1.78) 4 (3.20) 75 (6.00) Antibiotics*, 403 (22.12) 3,598 (19.76) 179 (23.28) 1,546 (20.10) 16 (12.80) 227 (18.16) Muscle relxnts*,, 173 (9.50) 399 (2.19) 50 (6.50) 153 (1.99) 20 (16.00) 37 (2.96) Antipsychotics*, 122 (6.70) 387 (2.13) 54 (7.02) 160 (2.08) 5 (4.00) 20 (1.60) Anti-Prkinson drugs*,, 23 (1.26) 54 (0.30) 8 (1.04) 17 (0.22) 3 (2.40) 4 (0.32) PPIs* 83 (4.56) 657 (3.61) 24 (3.12) 243 (3.16) 6 (4.80) 68 (5.44) For the 894 MS ptients whose type of MS ws determined through originl clinicl records MS multiple sclerosis, NSAIDs non-steroidl nti-inflmmtory drugs, PPMS primry progressive MS, PPIs proton pump inhibitors, RRMS relpsing-remitting MS * p \ 0.05 for comprison between ptients with MS nd mtched referent subjects (for ll MS ptients) p \ 0.05 for comprison between ptients with RRMS nd mtched referent subjects p \ 0.05 for comprison between ptients with PPMS nd mtched referent subjects Includes 64 ptients with secondry progressive MS higher HR ws not found for PPMS ptients [djusted HR 1.32 (95 % CI )]. It should be noted, however, tht the number of PPMS ptients ws smll. Discussion This lrge study of 1,822 people with MS in UK primry cre provides ntionl estimtes of ll-cuse mortlity mong this ptient group. We observed 1.7-fold incresed risk of ll-cuse mortlity for MS ptients compred with the generl popultion. This increse in risk is in line with reports from other lrge popultion-bsed cohorts [2 4, 18 21], lthough direct comprisons re difficult owing to differences in geogrphicl regions nd/or study periods. Consistent with other reports, MS ws the min recorded cuse of deth (40.8 %) in MS ptients in our study. This proportion is lower thn tht in other studies, lbeit from wide rnge of geogrphicl popultions, where MS ws the reported cuse of deth in more thn 50 % of ffected ptients [4]. Respirtory diseses, infections, crdiovsculr diseses nd cncers re other commonly reported cuses of deth in ptients with MS [2, 22], nd our results re consistent with these findings. It should be noted tht the rel cuses of deth in ptients with MS re not lwys recorded in ptient records or registries. While it is ccepted tht MS is not per se ftl disese, neither our study nor prior studies hve been ble to identify ll direct cuses of deth in these ptients. Thus, complete informtion on cuse of deth remins unttinble. The lower proportion of MS ptients with cncer s the cuse of deth compred to non-ms referents could be due to incresed susceptibility to cute cuses of deth (such s infections or cute crdiovsculr events). These cute nd sometimes ftl comorbidities my ct s competing risks, truncting the long ltency periods needed for neoplstic disese to express cliniclly. Current evidence suggests tht frequency of suicides my be higher in MS ptients [23]. In only three ptients ws suicide the recorded cuse of deth in our study (one MS ptient nd two referents), which ws insufficient to detect ny mteril difference between the ptient groups. The progressive nture of MS is reflected in our study in the incresing differences in ll-cuse mortlity rtes seen between MS ptients nd their mtched non-ms referents with incresing length of follow-up. It is interesting tht ll HRs were ttenuted when risk fctors for comedictions ssocited with MS were included in the model. This suggests tht some of the incresed risk for deth is ssocited with the comorbidities nd resulting comedictions
8 1514 J Neurol (2014) 261: Tble 4 Deth rte per 1,000 person-yers in ptients with MS nd mtched referent subjects overll, strtified by ge t first dignosis of MS, sex, nd type of MS CI confidence intervl, MS multiple sclerosis, RRMS relpsing-remitting MS, PPMS primry progressive MS For the 894 MS cses confirmed by originl clinicl records b Including 64 ptients with SPMS Deths (N) Popultion size Person-yers Deth rtes (95 % CI) Overll Ptients with MS 130 1,822 14, ( ) Referent subjects , , ( ) Age group t dignosis (yers) \30 Ptients with MS , ( ) Referent subjects 5 2,666 18, ( ) Ptients with MS , ( ) Referent subjects 48 5,217 40, ( ) Ptients with MS , ( ) Referent subjects 116 5,634 47, ( ) Ptients with MS , ( ) Referent subjects 180 3,380 27, ( ) C60 Ptients with MS ( ) Referent subjects 224 1,314 10, ( ) Sex Mle Ptients with MS , ( ) Referent subjects 228 4,801 37, ( ) Femle Ptients with MS 89 1,341 10, ( ) Referent subjects , , ( ) Type of MS RRMS Ptients with MS ,b 6, ( ) Referent subjects 183 7,690 62, ( ) PPMS Ptients with MS , ( ) Referent subjects 63 1,250 10, ( ) tht occur more frequently in ptients with MS. It is notble tht the HRs for deth in the MS cohort compred to the non-ms cohort were highest in the younger ptients nd decresed with incresing ge. It is possible tht the decresed bseline risk of deth in younger people contributed to the higher HR, while bseline risks incresed for ll ptients with incresing ge leding to lower HRs. We did not, however, find ny sttisticlly significnt difference in survivl between mles nd femles, lthough the djusted HR for ll-cuse mortlity ws higher for femles. Other reports concerning gender difference in survivl hve been mixed [2, 4, 18, 19]. MS ptients in this study were more likely to hve been dignosed with depression in the period between first MS symptoms nd first MS dignosis. Dignoses of depression in the yers before first symptoms were similr in the MS ptients nd their mtched non-ms referents. Given their timing, these findings cn be interpreted either s rective in the setting of neurologicl disese of uncertin etiology, or s direct result of neurl dmge cused by the ongoing inflmmtory process ffecting the CNS. In ny cse, these results highlight tht depression, together with the hevy burden it imposes on functionl sttus, becomes relevnt problem in MS subjects long before finl dignoses of MS cn be reched. The higher incidence of urinry trct infection in the months prior to MS dignosis is consistent with decresed mobility found in MS ptients, prticulrly those with PPMS. While the incidence of Prkinson s disese ws higher in the MS group compred to the non-ms referents, the bsolute number of
9 J Neurol (2014) 261: Fig. 1 Kpln Meier plot for the survivl probbilities (llcuse mortlity) of ptients \50 yers t index dte. MS multiple sclerosis. b Kpln Meier plot for the survivl probbilities (ll-cuse mortlity) of ptients C50 yers t index dte. MS multiple sclerosis Survivl Probbility 100.0% 95.0% 90.0% 85.0% 80.0% 75.0% 70.0% Log-rnk P-vlue : <.0001 Referent subjects Ptients with MS Time since index dte (yers) b 100.0% 95.0% Survivl Probbility 90.0% 85.0% 80.0% 75.0% 70.0% Log-rnk P-vlue : <.0001 Referent subjects Ptients with MS Time since index dte (yers) cses ws smll. Previous reports hve not found similr differences. It is possible tht t lest some of the 23 cses hd Prkinsonin symptoms due to compromise of the bsl gngli by the underlying neuro-inflmmtory process, but were misdignosed nd treted s idiopthic Prkinson s disese. Alterntively, the ssocition could be explined by unmesured confounders. Strengths of our study include the lrge smple size, the high qulity of the dtbse nd the controlled study design. The representtiveness of the study popultion mens tht the results cn be generlized to the UK s whole, thus the study hs high externl vlidity. In ddition, for some MS cses, we were ble to vlidte the dignosis by ccessing ptients originl clinicl records, which long with linkge to deth registry dt, enbled dditionl clinicl informtion to be obtined. We were lso ble to obtin nd nlyze dt on lrge number of potentil risk fctors for mortlity. Our study lso hs limittions. We were unble to vlidte the MS dignosis vi originl clinicl records for ll ptients, thus it is likely tht some misclssifiction of MS cses occurred. Any misclssifiction would likely hve been rndom, non-differentil, nd would hve hd little effect on the mortlity rtes in the study. Any effects on the HRs would likely hve been smll nd bised towrd the null. However, when we repeted the min nlyses for cses whose dignosis ws mde on originl clinicl records nd for cses whose dignosis ws mde from electronic records only, we found the results from the two groups to be consistent. When we repeted the nlyses gin, restricted to definite nd probble MS ptients, the results were similr to the full group nlysis (Online
10 1516 J Neurol (2014) 261: Tble 5 Hzrd rtios nd 95 % confidence intervls for ll-cuse mortlity mong MS cses versus mtched referent subjects Chrcteristic Deth in MS ptients N = 130 Deths in non-ms referents N = 573 HR (95 % CI) Model 1 Model 2 b Overll 130 (100) 573 (100) 2.30 ( ) 1.68 ( ) Age t first MS dignosis (yers) \30 8 (6.2) 5 (0.87) ( ) ( ) (15.4) 48 (8.4) 4.27 ( ) 3.29 ( ) (26.9) 116 (20.2) 3.13 ( ) 2.16 ( ) (23.1) 180 (31.4) 1.66 ( ) 1.33 ( ) C60 37 (28.5) 224 (39.1) 1.82 ( ) 1.47 ( ) Sex Mle 41 (31.5) 228 (39.8) 1.79 ( ) 1.31 ( ) Femle 89 (68.5) 345 (60.2) 2.63 ( ) 1.86 ( ) Type of MS c RRMS d 40 (30.8) 183 e (31.9) 1.94 ( ) 1.50 ( ) PPMS 12 (9.2) 63 f (11.0) 1.89 ( ) 1.32 ( ) CI confidence intervl, HR hzrd rtio, MS multiple sclerosis, PPMS primry progressive MS, RRMS relpsing-remitting MS, SPMS secondry progressive MS Adjusted for mtching vribles (ge, sex, index dte, GP, nd length of medicl history recorded before the index dte) b Adjusted for smoking nd comedictions (including ntidepressnts, nticonvulsnts, opioids, muscle relxnts) within 6 months before or t the index dte, in ddition to the mtching vribles c MS cses confirmed by originl clinicl pper records d Including ptients with SPMS e Mtched to ptients with RRMS f Mtched to ptients with PPMS Resources 4 7). We were lso unble to identify cuse of deth for round 15 % of decesed MS ptients nd 17 % of decesed referents, which my hve influenced comprisons of cuse of deth. However, we found the most common cuses of deths were consistent with those reported elsewhere [22]. Our study ws underpowered to explore risk fctors for cuse-specific mortlity, nd it is lso possible tht there ws some underestimtion of our reported ll-cuse mortlity rtes. This is becuse followup time my not hve been long enough to observe mortlity, especilly for MS cses identified between 2001 nd It is lso possible tht smll number of deths were not recorded by the GP though recording of deth is required of ll GPs nd this number should be miniml. In ddition, we were unble to evlute the influence of interferon bet, which hs been shown to slow disese progression [24 26] nd reduce ll-cuse mortlity [26 28] in ptients with RRMS. Although this my hve ffected our estimtes of ll-cuse mortlity mong RRMS ptients, it is unlikely to hve ffected the HRs ssocited with fctors found to be predictive of ll-cuse mortlity, s such confounding by indiction is unlikely. In summry, our findings show tht ptients with MS hve incresed ll-cuse mortlity rtes compred with the generl popultion, nd tht some of this increse is likely relted to the comorbidities tht occur more frequently in ptients with MS. Most deths in MS ptients re recorded s due to the disese itself. Acknowledgments This study ws funded by Byer HelthCre AG. We thnk Susn Bromley, Independent Medicl Writer (Oxford, UK) for ssistnce in the drfting nd editing the mnuscript, funded by Byer HelthCre AG. This study is bsed on dt from the Full Feture GPRD obtined under licence from the UK Medicines nd Helthcre Products Regultory Agency. Conflicts of interest Susn Jick nd Lin Li work for the BCDSP, which hs received reserch funding from Byer HelthCre AG for this study. Guido Flcone hs no conflicts of interest. Zdrvko Vssilev is slried employee of Byer HelthCre Phrmceuticls. Mri-Ann Wllnder ws slried employee of Byer HelthCre AG t the time of the study. Ethicl stndrd The conduct of this study ws pproved by the CPRD Independent Scientific Advisory Committee for UK Medicines nd Helthcre products Regultory Agency dtbse reserch. Open Access This rticle is distributed under the terms of the Cretive Commons Attribution License which permits ny use, distribution, nd reproduction in ny medium, provided the originl uthor(s) nd the source re credited.
11 J Neurol (2014) 261: References 1. Puglitti M, Rosti G, Crton H, Riise T, Drulovic J, Vecsei L, Milnov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13: Sclfri A, Knppertz V, Cutter G, Goodin DS, Ashton R, Ebers GC (2013) Mortlity in ptients with multiple sclerosis. Neurology 81: Herrett E, Thoms SL, Schoonen WM, Smeeth L, Hll AJ (2010) Vlidtion nd vlidity of dignoses in the Generl Prctice Reserch Dtbse: systemtic review. Br J Clin Phrmcol 69: Willims T, vn St TP, Puri S, Eton S (2012) Recent dvnces in the utility nd use of the Generl Prctice Reserch Dtbse s n exmple of UK Primry Cre Dt resource. Ther Adv Drug Sf 3: Alonso A, Jick SS, Hernn MA (2006) Allergy, histmine 1 receptor blockers, nd the risk of multiple sclerosis. Neurology 66: Alonso A, Jick SS, Jick H, Hernn MA (2006) Antibiotic use nd risk of multiple sclerosis. Am J Epidemiol 163: Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernn MA (2005) Recent use of orl contrceptives nd the risk of multiple sclerosis. Arch Neurol 62: Alonso A, Jick SS, Olek MJ, Hernn MA (2007) Incidence of multiple sclerosis in the United Kingdom: findings from popultion-bsed cohort. J Neurol 254: Bzelier MT, vn St T, Uitdehg BM, Cooper C, Leufkens HG, Vestergrd P, Bentzen J, de Vries F (2011) The risk of frcture in ptients with multiple sclerosis: the UK generl prctice reserch dtbse. J Bone Miner Res 26: Hernn MA, Jick SS (2006) Heptitis B vccintion nd multiple sclerosis: the jury is still out. Phrmcoepidemiol Drug Sf 15: Hernn MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigrette smoking nd the progression of multiple sclerosis. Brin 128: Hernn MA, Jick SS, Olek MJ, Jick H (2004) Recombinnt heptitis B vccine nd the risk of multiple sclerosis: prospective study. Neurology 63: Mckenzie IS, Mornt SV, Bloomfield GA, McDonld TM, O Riordn J (2014) Incidence nd prevlence of multiple sclerosis in the UK : descriptive study in the Generl Prctice Reserch Dtbse. J Neurol Neurosurg Psychitry 85: Polmn CH, Reingold SC, Edn G, Filippi M, Hrtung HP, Kppos L, Lublin FD, Metz LM, McFrlnd HF, O Connor PW, Sndberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Dignostic criteri for multiple sclerosis: 2005 revisions to the McDonld Criteri. Ann Neurol 58: Chrlson ME, Pompei P, Ales KL, McKenzie CR (1987) A new method of clssifying prognostic comorbidity in longitudinl studies: development nd vlidtion. J Chronic Dis 40: Kingwell E, vn der Kop M, Zho Y, Shirni A, Zhu F, Oger J, Tremlett H (2012) Reltive mortlity nd survivl in multiple sclerosis: findings from British Columbi, Cnd. J Neurol Neurosurg Psychitry 83: Llmohmed A, Bzelier MT, Vn St TP, Uitdehg BM, Leufkens HG, De Boer A, De Vries F (2012) Cuses of deth in ptients with multiple sclerosis nd mtched referent subjects: popultion-bsed cohort study. Eur J Neurol 19: Lery E, Morrissey S, Younq J, Coustns M, Le Pge E, Chperon J, Edn G (2007) Long-term survivl of ptients with multiple sclerosis in West Frnce. Mult Scler 13: Sumelhti ML, Hkm M, Elovr I, Pukkl E (2010) Cuses of deth mong ptients with multiple sclerosis. Mult Scler 16: Bronnum-Hnsen H, Koch-Henriksen N, Stenger E (2004) Trends in survivl nd cuse of deth in Dnish ptients with multiple sclerosis. Brin 127: Grytten Torkildsen N, Lie SA, Arseth JH, Nylnd H, Myhr KM (2008) Survivl nd cuse of deth in multiple sclerosis: results from 50-yer follow-up in Western Norwy. Mult Scler 14: Rgonese P, Aridon P, Slemi G, D Amelio M, Svettieri G (2008) Mortlity in multiple sclerosis: review. Eur J Neurol 15: Pompili M, Forte A, Plermo M, Stefni H, Lmis DA, Serfini G, Amore M, Girrdi P (2012) Suicide risk in multiple sclerosis: systemtic review of current literture. J Psychosom Res 73: Pty DW, Li DK (1993) Interferon bet-1b is effective in relpsing-remitting multiple sclerosis. II. MRI nlysis results of multicenter, rndomized, double-blind, plcebo-controlled tril. UBC MS/MRI Study Group nd the IFNB Multiple Sclerosis Study Group. Neurology 43: The IFNB Multiple Sclerosis Study Group (1993) Interferon bet- 1b is effective in relpsing-remitting multiple sclerosis. I. Clinicl results of multicenter, rndomized, double-blind, plcebo-controlled tril. The IFNB Multiple Sclerosis Study Group. Neurology 43: Trojno M, Pellegrini F, Fuini A, Policelli D, Zipoli V, Zimtore GB, Di Monte E, Portccio E, Lepore V, Livre P, Amto MP (2007) New nturl history of interferon-bet-treted relpsing multiple sclerosis. Ann Neurol 61: Goodin DS, Ebers GC, Cutter G, Cook SD, O Donnell T, Reder AT, Kremenchutzky M, Oger J, Rmett M, Beckmnn K, Knppertz V (2012) Cuse of deth in MS: long-term follow-up of rndomised cohort, 21 yers fter the strt of the pivotl IFNbet-1b study. BMJ Open 2(6). doi: /bmjopen Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Lngdon D, Rmett M, Beckmnn K, DeSimone TM, Knppertz V (2012) Survivl in MS: rndomized cohort study 21 yers fter the strt of the pivotl IFNbet-1b tril. Neurology 78:
Supplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationBMI and Mortality: Results From a National Longitudinal Study of Canadian Adults
nture publishing group BMI nd Mortlity: Results From Ntionl Longitudinl Study of Cndin Adults Hether M. Orpn 1, Jen-Mrie Berthelot 2,3, Mrk S. Kpln 4, Dvid H. Feeny 5,6, Bentson McFrlnd 7 nd Nncy A. Ross
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationIncreased Relative Mortality in Women With Severe Oxygen-Dependent COPD
CHEST Originl Reserch Incresed Reltive Mortlity in Women With Severe Oxygen-Dependent COPD Mgnus Ekström, MD ; Krl A. Frnklin, MD, PhD ; nd Kerstin E. Ström, MD, PhD COPD Bckground: Although the incidence
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationSafety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn,
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationMultiple sclerosis (MS) affects approximately. Triaging Patients with Multiple Sclerosis in the Emergency Department. Room for Improvement
Systemtic Review of Tools for Anxiety in MS MS CARE DELIVERY: CHALLENGES AND INVATIONS Triging Ptients with Multiple Sclerosis in the Emergency Deprtment Room for Improvement Heshm Abboud, MD, PhD; Krin
More informationURINARY incontinence is an important and common
Urinry incontinence in older people in the community: neglected problem? Helen Stoddrt, Jenny Donovn, Elise Whitley, Deborh Shrp nd In Hrvey SUMMARY Bckground: The prevlence nd impct of urinry incontinence
More informationReport of the Conference on Low Blood
1046 Report of the Conference on Low Blood Cholesterol: Mortlity Associtions Dvid Jcobs, PhD; Henry Blckburn, MD; Millicent Higgins, MD; Dwyne Reed, MD, PhD; Hiroysu Iso, MD; Grdner McMilln, MD, PhD; Jmes
More informationA series of recent studies and meta-analyses confirm
Originl Reserch Clinicl Medicine & Reserch Volume 11, Number 4: 210-218 2013 Mrshfield Clinic clinmedres.org Brest nd Prostte Cncer Survivors in Dibetic Cohort: Results from the Living With Dibetes Study
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationClinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population
Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn
More informationA Four-System Comparison of Patients With Chronic Illness: The Military Health System, Veterans Health Administration, Medicaid, and Commercial Plans
MILITARY MEDICINE, 174, 9:936, 2009 A Four-System Comprison of Ptients With Chronic Illness: The Militry Helth System, Veterns Helth Administrtion, Medicid, nd Commercil Plns Teres B. Gibson, PhD * ; Todd
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationInhaled Corticosteroids and the Risk of Pneumonia in People With Asthma
CHEST Originl Reserch Inhled Corticosteroids nd the Risk of Pneumoni in People With Asthm A Cse-Control Study Trici McKeever, PhD ; Timothy W. Hrrison, MD ; Richrd Hubbrd, MD ; nd Dominick Shw, MD ASTHMA
More informationTrends in Mortality From COPD Among Adults in the United States
[ Originl Reserch COPD ] Trends in Mortlity From COPD Among Adults in the United Sttes Erl S. Ford, MD, MPH BACKGROUND: COPD imposes lrge public helth burden interntionlly nd in the United Sttes. The objective
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationSummary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)
Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationPatient Survival After Surgical Treatment of Rectal Cancer
Originl Article Ptient Survivl After Surgicl Tretment of Rectl Cncer Impct of Surgeon nd Hospitl Chrcteristics Dvid A. Etzioni, MD, MSHS 1,2 ; Toni M. Young-Fdok, MD, MS 1 ; Robert R. Cim, MD, MA 2,3 ;
More informationEuropean Journal of Internal Medicine
Europen Journl of Internl Medicine 22 (2011) 399 406 Contents lists vilble t ScienceDirect Europen Journl of Internl Medicine journl homepge: www.elsevier.com/locte/ejim Originl rticle Incidence of cute
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationFactors influencing help seeking in mentally distressed young adults: a cross-sectional survey
L Biddle, D Gunnell, D Shrp nd J L Donovn Fctors influencing help seeking in mentlly distressed young dults: cross-sectionl survey Lucy Biddle, Dvid Gunnell, Debbie Shrp nd Jenny L Donovn SUMMARY Bckground:
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationMETHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY
METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY 1.0 SCOPE AND APPLICATION 1.1 Method 4010 is procedure for screening solids such s soils, sludges, nd queous medi such s wste wter nd lechtes
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationIn 2006, the prevalence of bipolar
With Bipolr Disorder Annette M. Mtthews, MD; Vness B. Wilson, BA; Suznne H. Mitchell, PhD; nd Peter Huser, MD This study of smoking ehviors nd smoking chrcteristics in veterns with ipolr disorder contriutes
More informationPotential for Interactions Between Dietary Supplements and Prescription Medications a
CLINICAL RESEARCH STUDY Potentil for Interctions Between Dietry Supplements nd Prescription Medictions Amit Sood, MD, MSc, Rich Sood, MD, b Frncis J. Brinker, ND, Rvneet Mnn, MBBS, c Lur L. Loehrer, Dietlind
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationRisk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort
Specil Report Risk of Colorectl Cncer by Subsite in Swedish Prostte Cncer Cohort Yunxi Lu, MD, PhD, Rickrd Ljung, MD, PhD, Ann Mrtling, MD, PhD, nd Mts Lindbld, MD, PhD Bckground: The reltionship between
More informationEffectiveness of Belt Positioning Booster Seats: An Updated Assessment
ARTICLES Effectiveness of Belt Positioning Booster Sets: An Updted Assessment AUTHORS: Kristy B. Arbogst, PhD, Jessic S. Jermkin, DSc, Michel J. Klln, MS, b nd Dennis R. Durbin, MD, MSCE,b Center for Injury
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationUrinary Tract Infection in Men
C H A P T E R 1 9 Urinry Trct Infection in Men Toms L. Griebling, MD Associte Professor & Vice Chir of Urology University of Knss Knss City, Knss Contents INTRODUCTION........................................623
More informationImpact of GP reminders on follow-up of abnormal cervical cytology:
Reserch Bettin Kjær Kristinsen, Berit Andersen, Flemming Bro, Hns Svnholm nd Peter Vedsted Impct of GP reminders on follow-up of bnorml cervicl cytology: before fter study in Dnish generl prctice Abstrct
More informationAppendix J Environmental Justice Populations
Appendix J Environmentl Justice s [This pge intentionlly left blnk] Tble of Contents REFERENCES...J-2 Pge LIST OF TABLES Pge Tble J-1: Demogrphic Overview of Bruinsburg Site Project Are... J-3 Tble J-2:
More informationLevel of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study
646863MSJ0010.1177/1352458516646863Multiple Sclerosis JournlK Bjørnevik, T Riise reserch-rticle2016 MULTIPLE SCLEROSIS JOURNAL MSJ Originl Reserch Pper Level of eduction nd multiple sclerosis risk over
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationRisk factors for testicular germ cell tumours by histological tumour type
Article no. bjoc.1999.0611 Risk fctors for testiculr germ cell tumours by histologicl tumour type CAC Couplnd 1, CED Chilvers 1, G Dvey 2, MC Pike 3, RTD Oliver 4 nd D Formn 2 on behlf of the United Kingdom
More informationRapid communications Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012
Rpid communictions Incresed detection of Mycoplsm pneumonie infection in children in Englnd nd Wles, October 2011 to Jnury 2012 V J Chlker (vicki.chlker@hp.org.uk) 1, T Stocki 1, D Litt 1, A Berminghm
More informationProstate cancer is among the most common malignancies
Implictions of Evolving Delivery System Reforms for Prostte Cncer Cre Brent K. Hollenbeck, MD, MS; Mggie J. Bierlein, MS; Smuel R. Kufmn, MS; Lindsey Herrel, MD; Ted A. Skolrus, MD, MPH; Dvid C. Miller,
More informationChronic obstructive pulmonary disease (COPD) is the third
METHODS Clims-Bsed Risk Model for First Severe COPD Excerbtion Richrd H. Stnford, PhrmD, MS; Arpit Ng, PhD, MBA, MS; Dougls W. Mpel, MD; Todd A. Lee, PhD; Richrd Rosiello, MD; Michel Schtz, MD; Frncis
More informationFat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice
Originl ppers Ft intke in ptients newly dignosed with type 2 dibetes: 4-yer follow-up study in generl prctice Floris A vn de Lr, Eloy H vn de Lisdonk, Peter L B J Lucssen, J M H Tigchelr, Sski Meyboom,
More informationPrime Enrollees Consumer Watch NHC Patuxent River FY 2016 Defense Health Cost Assessment & Program Evaluation
Prime Enrollees Consumer Wtch NHC Ptuxent River 16 Defense Helth Cost Assessment & Progrm Evlution NHC Ptuxent River: Smple size-1,457 Response rte-1.2% Source: Helth Cre Survey of DoD Beneficiries Inside
More informationDid introduction of pneumococcal vaccines in the Netherlands decrease the need for respiratory antibiotics in children? Analysis of 2002 to 2013 data
Reserch rticles Did introduction of pneumococcl vccines in the Netherlnds decrese the need for respirtory ntibiotics in children? Anlysis of 2002 to 2013 dt G Gefenite (g.gefenite@lumnus.rug.nl) 1,2, M
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationReports of cases of AIDS, HIV infection, and HIV/AIDS 1
Reports of cses of AIDS, HIV infection, nd HIV/AIDS 1 The HIV/AIDS Surveillnce Report is published nnully by the Division of HIV/AIDS Prevention Surveillnce nd Epidemiology, Ntionl Center for HIV, STD,
More informationLifetime and 12-Month Prevalence of Psychiatric Disorders in 8,169 Male Vietnam War Era Veterans
MILITARY MEDICINE, 169, 11:896, 2004 Lifetime nd 12-Month Prevlence of Psychitric Disorders in 8,169 Mle Vietnm Wr Er Veterns Gurntor: Seth A. Eisen, MD Contributors: Seth A. Eisen, MD* ; Kristin H. Griffith,
More informationFertility in Norwegian testicular cancer patients
DOI: 0.054/ bjoc.999.0989, vilble online t http://www.idelibrry.com on Fertility in Norwegin testiculr cncer ptients SD Fosså nd Ø Krvdl 2 The Norwegin Rdium Hospitl, Montebello, N-030 Oslo, Norwy; 2 The
More informationComparison of three simple methods for the
J. clin. Pth. (1967), 2, 5 Comprison of three simple methods for the ssessment of 'free' thyroid hormone T. M. D. GIMLETTE1 From the Rdio-Isotope Lbortory, St. Thoms's Hospitl, London SYNOPSIS A dilysis
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationAnalysis of Risk Factors for the Development of Incisional and Parastomal Hernias in Patients after Colorectal Surgery
Originl Article Journl of the Koren Society of J Koren Soc Coloproctol 2012;28(6):299-303 http://dx.doi.org/10.3393/jksc.2012.28.6.299 pissn 2093-7822 eissn 2093-7830 Anlysis of Risk Fctors for the Development
More informationResearch Article Potential Extensions of the US FRAX Algorithm
Journl of Osteoporosis Volume 2012, Article ID 528790, 8 pges doi:10.1155/2012/528790 Reserch Article Potentil Extensions of the US FRAX Algorithm L. Joseph Melton III, 1, 2 Elizbeth J. Atkinson, 3 Sr
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationWhat Drives Prescribing of Asthma Medication to Children? A Multilevel Population-Based Study. Ann Fam Med 2009;7: DOI: /afm.910.
Wht Drives Prescribing of Asthm Mediction to Children? A Multilevel Popultion-Bsed Study Mir G. P. Zuidgeest, PhrmD, PhD 1,3 Liset vn Dijk, PhD 2 Peter Spreeuwenberg, MA 2 Henriëtte A. Smit, MD, PhD 3
More informationEpidemiology of the Viral Hepatitis-HIV Syndemic in San Francisco: A Collaborative Surveillance Approach
Dt Hrmoniztion nd Registry Mtching Epidemiology of the Virl Heptitis-HIV Syndemic in Sn Frncisco: A Collbortive Surveillnce Approch Meliss A. Snchez, PhD, MA Susn Scheer, PhD, MPH b Sue Shllow, MPH, CACLS
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationImplications of iron deficiency/anemia on the classification of diabetes using HbA1c
OPEN Cittion: Nutrition & Dibetes (201), e166; doi:10.1038/nutd.201.16 www.nture.com/nutd ORIGINAL ARTICLE Implictions of iron /nemi on the clssifiction of dibetes using SM Attrd 1, AH Herring 2,3, H Wng
More informationUrinary Tract Infection in Women
C H A P T E R 1 8 Urinry Trct Infection in Women Toms L. Griebling, MD Associte Professor & Vice Chir of Urology University of Knss Knss City, Knss Contents INTRODUCTION........................................589
More informationAnalysis of Regulatory of Interrelated Activity of Hepatocyte and Hepatitis B Viruses
Interntionl Journl of Biomedicl Mterils Reserch 8 6(): -7 http://www.sciencepublishinggroup.com/j/ijbmr doi:.648/j.ijbmr.86. ISSN: 33-756 (Print) ISSN: 33-7579 (Online) Anlysis of Regultory of Interrelted
More informationORIGINAL RESEARCH & CONTRIBUTIONS
Effect of Advncing Age nd Multiple Chronic Conditions on Mortlity in Ptients with End-Stge Renl Disese fter Implntble Crdioverter-Defibrilltor Plcement Ashok Krishnswmi, MD, MAS; Mry-Lou Kiley, MBA; Fith
More informationCharacteristics of hip involvement in patients with ankylosing spondylitis in Korea
ORIGINAL ARTICLE Koren J Intern Med 2017;32:158-164 Chrcteristics of hip involvement in ptients with nkylosing spondylitis in Kore Hyemin Jeong, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Jejoon Lee, Eun-Mi
More informationORIGINAL ARTICLE. Diagnostic Signs of Accommodative Insufficiency. PILAR CACHO, OD, ÁNGEL GARCÍA, OD, FRANCISCO LARA, OD, and M A MAR SEGUÍ, OD
1040-5488/02/7909-0614/0 VOL. 79, NO. 9, PP. 614 620 OPTOMETRY AND VISION SCIENCE Copyright 2002 Americn Acdemy of Optometry ORIGINAL ARTICLE Dignostic Signs of Accommodtive Insufficiency PILAR CACHO,
More informationResearch Article Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians
Hindwi Publishing Corportion Journl of Cncer Epidemiology Volume 2012, Article ID 294730, 11 pges doi:10.1155/2012/294730 Reserch Article Ptterns of Cncer Genetic Testing: A Rndomized Survey of Oregon
More information